Tokumaru Y - Search Results

1

Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).

Futamura M, Ishihara K, Nagao Y, Ogiso A, Niwa Y, Nakada T, Kawaguchi Y, Ikawa A, Kumazawa I, Mori R, Kitazawa M, Hosono Y, Kuno M, Kawajiri M, Nakakami A, Takeuchi M, Morikawa A, Tokumaru Y, Katagiri Y, Asano Y, Mushika Y, Shimokawa T, Matsuhasih N. Futamura M, et al. Among authors: tokumaru y. Breast Cancer. 2023 Mar;30(2):293-301. doi: 10.1007/s12282-022-01425-2. Epub 2023 Jan 7. Breast Cancer. 2023. PMID: 36609911 Free PMC article. Clinical Trial.

2

DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells.

Tajirika T, Tokumaru Y, Taniguchi K, Sugito N, Matsuhashi N, Futamura M, Yanagihara K, Akao Y, Yoshida K. Tajirika T, et al. Among authors: tokumaru y. Int J Mol Sci. 2018 Jul 9;19(7):2005. doi: 10.3390/ijms19072005. Int J Mol Sci. 2018. PMID: 29987267 Free PMC article.

3

The mode of progressive disease affects the prognosis of patients with metastatic breast cancer.

Mori R, Futamura M, Morimitsu K, Asano Y, Tokumaru Y, Kitazawa M, Yoshida K. Mori R, et al. Among authors: tokumaru y. World J Surg Oncol. 2018 Aug 14;16(1):169. doi: 10.1186/s12957-018-1472-9. World J Surg Oncol. 2018. PMID: 30107807 Free PMC article.

4

Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase.

Tokumaru Y, Tajirika T, Sugito N, Kuranaga Y, Shinohara H, Tsujino T, Matsuhashi N, Futamura M, Akao Y, Yoshida K. Tokumaru Y, et al. Int J Mol Sci. 2019 Apr 5;20(7):1697. doi: 10.3390/ijms20071697. Int J Mol Sci. 2019. PMID: 30959742 Free PMC article.

5

Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer.

Matsuhashi N, Takahashi T, Fujii H, Suetsugu T, Fukada M, Iwata Y, Tokumaru Y, Imai T, Mori R, Tanahashi T, Matsui S, Imai H, Tanaka Y, Yamaguchi K, Futamura M, Yoshida K. Matsuhashi N, et al. Among authors: tokumaru y. Mol Clin Oncol. 2019 Oct;11(4):390-396. doi: 10.3892/mco.2019.1899. Epub 2019 Jul 18. Mol Clin Oncol. 2019. PMID: 31475067 Free PMC article.

6

KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.

Tokumaru Y, Oshi M, Katsuta E, Yan L, Satyananda V, Matsuhashi N, Futamura M, Akao Y, Yoshida K, Takabe K. Tokumaru Y, et al. Am J Cancer Res. 2020 Mar 1;10(3):897-907. eCollection 2020. Am J Cancer Res. 2020. PMID: 32266098 Free PMC article.

7

High Expression of miR-34a Associated with Less Aggressive Cancer Biology but Not with Survival in Breast Cancer.

Tokumaru Y, Katsuta E, Oshi M, Sporn JC, Yan L, Le L, Matsuhashi N, Futamura M, Akao Y, Yoshida K, Takabe K. Tokumaru Y, et al. Int J Mol Sci. 2020 Apr 26;21(9):3045. doi: 10.3390/ijms21093045. Int J Mol Sci. 2020. PMID: 32357442 Free PMC article.

8

High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer.

Tokumaru Y, Asaoka M, Oshi M, Katsuta E, Yan L, Narayanan S, Sugito N, Matsuhashi N, Futamura M, Akao Y, Yoshida K, Takabe K. Tokumaru Y, et al. Int J Mol Sci. 2020 May 1;21(9):3213. doi: 10.3390/ijms21093213. Int J Mol Sci. 2020. PMID: 32370060 Free PMC article.

9

Intratumoral Adipocyte-High Breast Cancer Enrich for Metastatic and Inflammation-Related Pathways but Associated with Less Cancer Cell Proliferation.

Tokumaru Y, Oshi M, Katsuta E, Yan L, Huang JL, Nagahashi M, Matsuhashi N, Futamura M, Yoshida K, Takabe K. Tokumaru Y, et al. Int J Mol Sci. 2020 Aug 11;21(16):5744. doi: 10.3390/ijms21165744. Int J Mol Sci. 2020. PMID: 32796516 Free PMC article.

10

M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer.

Oshi M, Tokumaru Y, Asaoka M, Yan L, Satyananda V, Matsuyama R, Matsuhashi N, Futamura M, Ishikawa T, Yoshida K, Endo I, Takabe K. Oshi M, et al. Among authors: tokumaru y. Sci Rep. 2020 Oct 6;10(1):16554. doi: 10.1038/s41598-020-73624-w. Sci Rep. 2020. PMID: 33024179 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

173 results

Search Page

Filters